Abstract
The purpose of this work was to compare technetium-99m-diphosphono-propanedicarboxylate (DPD) and iodine- 123-metaiodobenzylguanidine (MIBG) scans in the diagnosis and follow-up of neuroblastoma, and to study the role of histological differentiation in the uptake of MIBG. The uptake of MIBG and of DPD were studied retrospectively in 27 patients with neuroblastoma (primary, residual and recurrent tumours as well as bone and bone marrow metastases). The findings were related to the histological classification of the tumours as neuroblastoma (N1), differentiating neuroblastoma (N2) or ganglioneuroblastoma (N3). Uptake of MIBG by the primary tumour occurred in 17 of 19 patients, either at diagnosis or during follow-up. There were only two false-negatives with MIBG, both of which were N3. Ten patients were studied preoperatively with both MIBG and DPD. The primary tumour showed MIBG uptake in nine of the ten and DPD uptake in eight of them. Thirty-five sites of cortical bone metastasis were shown in eight patients by both MIBG and DPD, 12 sites in seven patients by MIBG only and seven sites in five patients by DPD only. In 14 patients both MIBG and bone scan were negative. Overall, MIBG demonstrated more lesions than DPD. Retrospectively several hot spots seen only with the bone scan are to be considered as false-positive. The highest incidence of false-negative MIBG and bone scans was observed in ganglioneuroblastoma with a predominance of the more mature component (ganglioneuroma).
Similar content being viewed by others
References
Lumbroso J, Guermazi F, Hartmann O, et al. Sensibilité et spécificité de la scintigraphie à la Métaiodobenzylguanidine dans l'exploration des neuroblastomes, analyse de 115 examens.Cancer 1988; 75: 97–106.
Feine U, Müller-Schauenburg W, Treuner J, Klingenbiel T. Metaiodobenzylguanidine labeled with123I/131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986.Med Pediatr Oncol 1987; 15: 181–187.
Hoefnagel CA, Voûte PA, De Kraker J, Markuse HR. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine.J Nucl Med 1987; 28: 308–314.
Miceli A, Nespoli L, Burgio GR, Aprile C, Carena M, Spaonaro R. The role of131I benzylguanidine in the diagnosis and follow-up of neuroblastoma.Pediatr Hematol Oncol 1986; 3: 37–47.
Voûte PA, Hoefnagel CA, De Kraker J.131I-Meta-iodobenzylguanidine in diagnosis and treatment of neuroblastoma.Cancer 1988; 75: 107–111.
Bomanji J, Conry BG, Britton KE, Reznek RH. Imaging neural crest tumors with123I-metaiodobenzylguanidine and X-ray computed tomography. A comparative study.Clin Radiol 1988; 39: 502–506.
Müller-Gärtner HA, Ertmann R, Helmke K. Meta-iodobenzylguanidine scintigraphy in neuroblastoma — a comparison with conventional X-ray and ultrsound.Pediatr Hematol Oncol 1986; 3: 97–109.
Sisson JC, Frager MS, Gross MD, et al. Scintigraphic localisation of pheochromocytoma.N Engl J Med 1981; 305: 12–17.
Kimming B, Brandeis WE, Eisenhut M, Bubeck B, Hermann HJ, Zum Winkel K. Szintigraphische Darstellung eines Neuroblastoms.Nucl Compact 1984; 14: 26–29.
Treuner J, Feine U, Niethammer D, et al. Scintigraphic imaging of neuroblastoma with [131I]Iodobenzylguanidine.Lancet 1984; I: 333–334.
Troncone L, Rufini V, Montemaggi P, Danza FM, Lasorella A, Mastrangelo R. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine.Eur J Nucl Med 1990; 16: 325–335.
Fischer M, Wehinger H, Kraus C, Ritter J, Schröter W. Treatment of neuroblastoma with131I-metaiodobenzylguanidine. Experience of the Münster/Kassel group.Med Pediatr Oncol 1987; 15: 196–198.
Guerra P. Possibilita diagnostiche e terapeutiche della MIBG nel neuroblastoma.Ped Med Chir 1990; 12: 663–668.
Shulkin BL, Shapiro B, Hutchinson RJ. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma.J Nucl Med 1992; 33: 1735–1740.
Jacobs A, Delree M, Desprechins B, et al. Consolidating the role of I-MIBG scintigraphy in childhood neuroblastoma: five years of clinical experience.Pediatr Radiol 1990; 20: 157–159.
Sautter-Bihl M-L, Bihl H, Heinze HG. Stellenwert der99mTc-MDP-Skelettszintigraphie beim Neuroblastom.Nucl Med 1991; 30: 7–12.
Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireax C, Pritchard J. Skeletal assesment in neuroblastoma — the pitfalls of iodine-123-MIBG scans.J Nucl Med 1990; 31: 129–134.
Hall-Craggs MA, Shaw D, Pritchard J, Gordon I. Metastatic neuroblastoma. new abnormalities on bone scintigraphy may not indicate tumor recurrence.Skeletal Radiol 1990; 19: 33–36.
Feggi L, Degli Uberti E, Pansini GC, et al. Pitfalls in scintigraphic detection of neuroendocrine tumors.Eur J Nucl Med 1992; 19: 214–218.
Schmiegelow K, Siimes MA, Agertoft L, et al. Radio-iodobenzylguanidine scintigraphy of neuroblastoma: conflicting results, when compared with standard investigations.Med Pediatr Oncol 1989; 17: 126–130.
Moyes JSE, Babich JW, Carter R, Meller ST, Agrawal M, McElwain TJ. Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: correlation with tumor histopathology.J Nucl Med 1989; 30: 474–480.
Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.J Clin Oncol 1988; 6: 1874–1881.
David R, Lamki N, Fan S, et al. The many faces of neuroblastoma.Radiographics 1989; 9: 859–882.
Haas D, Ablin AR, Miller C, Zoger S, Matthay KK. Complete pathologic maturation and regression of stage IVs neuroblastoma without treatment.Cancer 1988; 62: 818–825.
Evans AE, D'Angio GJ, Sather HN, et al. A comparison of four staging systems for localized and regional neuroblastoma: a report from the Children's Cancer Study Group.J Clin Oncol 1990; 8: 678–688.
Joshi VV, Cantor AB, Brodeur GM, et al. Correlation between morphologic and other prognostic markers of neuroblastoma.Cancer 1993; 71: 3173–3181.
Joshi VV, Cantor AB, Altshuler G, et al. Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification.Cancer 1992: 69: 2183–2196.
Lastoria S, Maurea S, Caraco C, et al. Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: comparison with computed tomography and ultrasonography.Eur J Nucl Med 1993; 20: 1161–1167.
Clerico A, Jenkner A, Castello MA, Ciofetta G, Lucarelli C, Codini M. Functionally active ganglioneuroma with increased plasma and urinary catecholamines and positive iodine 131-meta-iodobenzylguanidine scintigraphy.Med Pediatr Oncol 1991; 19: 329–333.
Paltiel HJ, Gelfand MJ, Elgazzar AH, et al. Neural crest tumors; I-123 MIBG imaging in children.Radiology 1994; 190: 117–121.
Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled metaiodobenzylguanidine (MIBG).Nucl Med Commun 1992; 13: 513–521.
Osmsnagaoglou K, Lippens M, Benoit Y, Obrie E, Schelstraete K, Simons M. A comparison of iodine-123 meta-iodobenzylguanidine scintigraphy and single bone marrow aspiration biopsy in the diagnosis and follow-up of 26 children with neuroblastoma:Eur J Nucl Med 1993; 20: 1154–1160.
Corbett Rolliff J, Fairley N, Moyes J, et al. A prospective comparison between magnetic resonance imaging, meta-iodo-benzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma.Eur J Cancer 1991; 27: 1560–1564.
Benz-Bohm G, Gross-Fengels W, Wiedemann B, Linden A. Knochenmarkmetastasierung bei Neuroblastom. MRT im Vergleich zur Knochenmarkzytologie und MIBG-Szintigraphie.Fortschr Röntgenstr 1990; 152: 523–527.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hadj-Djilani, N.L., Lebtahi, N.E., Bischof Delaloye, A. et al. Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med 22, 322–329 (1995). https://doi.org/10.1007/BF00941848
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00941848